CRISPR Therapeutics AG
CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programsā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$52.75
Price-0.15%
-$0.08
1Y
Price
Market Cap
$5.088b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-8637.1%
EBITDA Margin-8431.5%
Net Profit Margin-7503.5%
Free Cash Flow Margin-8637.1%
EBITDA Margin-8431.5%
Net Profit Margin-7503.5%
Free Cash Flow MarginRevenue
$4.103m
+16.9%
1y CAGR-54.5%
3y CAGR+21149.7%
5y CAGREarnings
-$568.534m
+2.3%
1y CAGR-65.0%
3y CAGR-29.6%
5y CAGREPS
-$6.22
+3.9%
1y CAGR-56.3%
3y CAGR-23.0%
5y CAGRBook Value
$1.815b
$2.726b
Assets$911.264m
Liabilities$787.642m
DebtDebt to Assets
28.9%
-1.6x
Debt to EBITDAFree Cash Flow
-$401.176m
-16.0%
1y CAGR-36.2%
3y CAGR-14.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company